D-Mannose | Carubinose;NSC 26247;(+)-Mannose | D-(+)-甘露糖 | Sugar

D-Mannose/D-甘露糖 {[allProObj[0].p_purity_real_show]}

货号：A302444 同义名： D-(+)-甘露糖 / Carubinose; NSC 26247

D-Mannose是一种糖类，可以参与蛋白质的糖基化和体内代谢过程。

D-Mannose/D-甘露糖化学结构
CAS号：3458-28-4

D-Mannose/D-甘露糖 3D分子结构
CAS号：3458-28-4

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

D-Mannose/D-甘露糖细胞实验

Cell Line Human macrophages derived from peripheral blood monocytes RAW264.7 cells Rat kidney epithelial NRK-52E cells Human normal intestinal FHs 74 Int cells Human breast cancer MDA-MB-468 cells Human lung adenocarcinoma PC-9 cells Melanoma A375 cells peritoneal macrophages colon organoids intestinal epithelial cells (IECs) RAW 264.7 murine macrophage cell line Mouse bone marrow-derived macrophages (BMDMs) bone marrow-derived monocytes Lymphoma YAC-1 cells Fibrosarcoma MethA cells Rat bone marrow monocytes (rBMMs) HaCaT cells NHEK cells Primary mouse chondrocytes gdT cells Primary mouse hepatocytes (PMHs)	Concentration	Treated Time	Description	References
Human macrophages derived from peripheral blood monocytes	11 mM	24 h	Inhibited IL-1β production	Nat Commun. 2020 Dec 11;11(1):6343.
RAW264.7 cells	25 mM		Inhibited osteoclast proliferation and fusion	J Transl Med. 2023 Jan 9;21(1):8.
Rat kidney epithelial NRK-52E cells	20 mM	2 h	To investigate the inhibitory effect of D-Mannose on cisplatin-induced GSDME-dependent pyroptosis. Results showed that D-Mannose substantially suppressed cisplatin-induced pyroptotic morphology, GSDME cleavage, and LDH release.	Cell Res. 2023 Dec;33(12):904-922.
Human normal intestinal FHs 74 Int cells	20 mM	2 h	To investigate the inhibitory effect of D-Mannose on cisplatin-induced GSDME-dependent pyroptosis. Results showed that D-Mannose substantially suppressed cisplatin-induced pyroptotic morphology, GSDME cleavage, and LDH release.	Cell Res. 2023 Dec;33(12):904-922.
Human breast cancer MDA-MB-468 cells	20 mM	2 h	To investigate the inhibitory effect of D-Mannose on raptinal-induced GSDME-dependent pyroptosis. Results showed that in GSDME-overexpressing MDA-MB-468 cells, raptinal-induced pyroptosis was clearly inhibited by mannose.	Cell Res. 2023 Dec;33(12):904-922.
Human lung adenocarcinoma PC-9 cells	20 mM	2 h	To investigate the inhibitory effect of D-Mannose on raptinal-induced GSDME-dependent pyroptosis. Results showed that in GSDME-overexpressing PC-9 cells, raptinal-induced pyroptosis was clearly inhibited by mannose.	Cell Res. 2023 Dec;33(12):904-922.
Melanoma A375 cells	20 mM	2 h	To investigate the inhibitory effect of D-Mannose on CCCP/FeSO4-induced GSDME-dependent pyroptosis. Results showed that D-Mannose dramatically reversed CCCP/iron-induced pyroptosis, including pyroptotic morphology, GSDME cleavage, and lactate dehydrogenase (LDH) release.	Cell Res. 2023 Dec;33(12):904-922.
peritoneal macrophages	20 mM	12 h	To assess the effect of mannose on TNF-α production in macrophages. Results showed that mannose significantly suppressed LPS-induced TNF-α production, and this effect was achieved by reducing GAPDH binding to TNF-α mRNA.	Cell Mol Immunol. 2023 Feb;20(2):119-130.
colon organoids	10 mM	24 h	To investigate the effect of mannose on inflammation-induced damage in colon organoids. Results showed that mannose significantly rescued the viability of organoids and reduced the expression of ERS markers.	Cell Mol Immunol. 2023 Feb;20(2):119-130.
intestinal epithelial cells (IECs)	10 mM	24 h	To evaluate the effect of mannose on inflammation-induced endoplasmic reticulum stress (ERS). Results showed that mannose significantly reduced the expression of GRP78 and CHOP, indicating its ability to alleviate inflammation-induced ERS.	Cell Mol Immunol. 2023 Feb;20(2):119-130.
RAW 264.7 murine macrophage cell line	11 mM	24 h	Inhibited pro-inflammatory cytokine IL-1β production	Nat Commun. 2020 Dec 11;11(1):6343.
Mouse bone marrow-derived macrophages (BMDMs)	11 mM	24 h	Inhibited LPS-induced Il1b gene expression and IL-1β secretion	Nat Commun. 2020 Dec 11;11(1):6343.
bone marrow-derived monocytes	0 mM, 1 mM, 10 mM, 50 mM	4 h	To assess the effect of D-mannose on macrophage phagocytic capability. It was found that as D-mannose concentration increased, the phagocytic capability of M1 and M2 macrophages significantly decreased.	Proc Natl Acad Sci U S A. 2021 Nov 2;118(44):e2107663118.
Lymphoma YAC-1 cells	50 mM	4 h	All tested sugars (including D-mannose) blocked NK cell-mediated cytotoxicity (CMC) against YAC-1 target cells	Proc Natl Acad Sci U S A. 1980 May;77(5):2895-8.
Fibrosarcoma MethA cells	50 mM	24 h	D-Mannose significantly blocked NC cell-mediated cytotoxicity (CMC) against MethA target cells	Proc Natl Acad Sci U S A. 1980 May;77(5):2895-8.
Rat bone marrow monocytes (rBMMs)	25 mM	4 days	Suppressed osteoclast proliferation and bone resorption capacity	J Transl Med. 2023 Jan 9;21(1):8.
HaCaT cells	5 mM	24-48 h	D-Mannose inhibited AGEs generation and protected the physiological functions of keratinocytes under high glucose conditions.	Mol Med. 2025 Jan 18;31(1):15.
NHEK cells	5 mM	24-48 h	D-Mannose inhibited AGEs generation and protected the physiological functions of keratinocytes under high glucose conditions.	Mol Med. 2025 Jan 18;31(1):15.
Primary mouse chondrocytes	25 mM	24 and 48 h	To evaluate the protective effect of D-mannose on IL-1β-induced chondrocyte ferroptosis. Results showed that D-mannose significantly attenuated IL-1β-induced chondrocyte ferroptosis by inhibiting lipid peroxidation and upregulating the expression of GPX4 and SLC7A11.	Cell Prolif. 2021 Nov;54(11):e13134.
gdT cells	50 mM	72 h	To evaluate the impact of D-mannose on gdT cells, results showed that D-mannose treatment reduced the proliferation and glycolytic capabilities of gdT cells.	Front Immunol. 2022 Feb 28;13:840755.
Primary mouse hepatocytes (PMHs)	5 mM	24 h	To evaluate the effect of D-mannose on ethanol-induced lipid accumulation in hepatocytes. Results showed that D-mannose significantly reduced ethanol-induced elevation of intracellular TG and TC levels and confirmed reduced lipid droplet accumulation via BODIPY staining.	Front Immunol. 2022 Apr 7;13:877650.

Cell Line

Concentration

Treated Time

Description

References

Human macrophages derived from peripheral blood monocytes

11 mM

24 h

Inhibited IL-1β production

Nat Commun. 2020 Dec 11;11(1):6343.

RAW264.7 cells

25 mM

Inhibited osteoclast proliferation and fusion

J Transl Med. 2023 Jan 9;21(1):8.

Rat kidney epithelial NRK-52E cells

20 mM

2 h

To investigate the inhibitory effect of D-Mannose on cisplatin-induced GSDME-dependent pyroptosis. Results showed that D-Mannose substantially suppressed cisplatin-induced pyroptotic morphology, GSDME cleavage, and LDH release.

Cell Res. 2023 Dec;33(12):904-922.

Human normal intestinal FHs 74 Int cells

20 mM

2 h

Cell Res. 2023 Dec;33(12):904-922.

Human breast cancer MDA-MB-468 cells

20 mM

2 h

To investigate the inhibitory effect of D-Mannose on raptinal-induced GSDME-dependent pyroptosis. Results showed that in GSDME-overexpressing MDA-MB-468 cells, raptinal-induced pyroptosis was clearly inhibited by mannose.

Cell Res. 2023 Dec;33(12):904-922.

Human lung adenocarcinoma PC-9 cells

20 mM

2 h

To investigate the inhibitory effect of D-Mannose on raptinal-induced GSDME-dependent pyroptosis. Results showed that in GSDME-overexpressing PC-9 cells, raptinal-induced pyroptosis was clearly inhibited by mannose.

Cell Res. 2023 Dec;33(12):904-922.

Melanoma A375 cells

20 mM

2 h

To investigate the inhibitory effect of D-Mannose on CCCP/FeSO4-induced GSDME-dependent pyroptosis. Results showed that D-Mannose dramatically reversed CCCP/iron-induced pyroptosis, including pyroptotic morphology, GSDME cleavage, and lactate dehydrogenase (LDH) release.

Cell Res. 2023 Dec;33(12):904-922.

peritoneal macrophages

20 mM

12 h

To assess the effect of mannose on TNF-α production in macrophages. Results showed that mannose significantly suppressed LPS-induced TNF-α production, and this effect was achieved by reducing GAPDH binding to TNF-α mRNA.

Cell Mol Immunol. 2023 Feb;20(2):119-130.

colon organoids

10 mM

24 h

To investigate the effect of mannose on inflammation-induced damage in colon organoids. Results showed that mannose significantly rescued the viability of organoids and reduced the expression of ERS markers.

Cell Mol Immunol. 2023 Feb;20(2):119-130.

intestinal epithelial cells (IECs)

10 mM

24 h

To evaluate the effect of mannose on inflammation-induced endoplasmic reticulum stress (ERS). Results showed that mannose significantly reduced the expression of GRP78 and CHOP, indicating its ability to alleviate inflammation-induced ERS.

Cell Mol Immunol. 2023 Feb;20(2):119-130.

RAW 264.7 murine macrophage cell line

11 mM

24 h

Inhibited pro-inflammatory cytokine IL-1β production

Nat Commun. 2020 Dec 11;11(1):6343.

Mouse bone marrow-derived macrophages (BMDMs)

11 mM

24 h

Inhibited LPS-induced Il1b gene expression and IL-1β secretion

Nat Commun. 2020 Dec 11;11(1):6343.

bone marrow-derived monocytes

0 mM, 1 mM, 10 mM, 50 mM

4 h

To assess the effect of D-mannose on macrophage phagocytic capability. It was found that as D-mannose concentration increased, the phagocytic capability of M1 and M2 macrophages significantly decreased.

Proc Natl Acad Sci U S A. 2021 Nov 2;118(44):e2107663118.

Lymphoma YAC-1 cells

50 mM

4 h

All tested sugars (including D-mannose) blocked NK cell-mediated cytotoxicity (CMC) against YAC-1 target cells

Proc Natl Acad Sci U S A. 1980 May;77(5):2895-8.

Fibrosarcoma MethA cells

50 mM

24 h

D-Mannose significantly blocked NC cell-mediated cytotoxicity (CMC) against MethA target cells

Proc Natl Acad Sci U S A. 1980 May;77(5):2895-8.

Rat bone marrow monocytes (rBMMs)

25 mM

4 days

Suppressed osteoclast proliferation and bone resorption capacity

J Transl Med. 2023 Jan 9;21(1):8.

HaCaT cells

5 mM

24-48 h

D-Mannose inhibited AGEs generation and protected the physiological functions of keratinocytes under high glucose conditions.

Mol Med. 2025 Jan 18;31(1):15.

NHEK cells

5 mM

24-48 h

D-Mannose inhibited AGEs generation and protected the physiological functions of keratinocytes under high glucose conditions.

Mol Med. 2025 Jan 18;31(1):15.

Primary mouse chondrocytes

25 mM

24 and 48 h

To evaluate the protective effect of D-mannose on IL-1β-induced chondrocyte ferroptosis. Results showed that D-mannose significantly attenuated IL-1β-induced chondrocyte ferroptosis by inhibiting lipid peroxidation and upregulating the expression of GPX4 and SLC7A11.

Cell Prolif. 2021 Nov;54(11):e13134.

gdT cells

50 mM

72 h

To evaluate the impact of D-mannose on gdT cells, results showed that D-mannose treatment reduced the proliferation and glycolytic capabilities of gdT cells.

Front Immunol. 2022 Feb 28;13:840755.

Primary mouse hepatocytes (PMHs)

5 mM

24 h

To evaluate the effect of D-mannose on ethanol-induced lipid accumulation in hepatocytes. Results showed that D-mannose significantly reduced ethanol-induced elevation of intracellular TG and TC levels and confirmed reduced lipid droplet accumulation via BODIPY staining.

Front Immunol. 2022 Apr 7;13:877650.

D-Mannose/D-甘露糖动物实验

Species C57BL/6 mice Mice Mice (Balb/c) Mice Rats Balb/c mice C57BL/6J mice C57BL/6 mice C57BL/6 mice	Animal Model Cisplatin-induced small intestine and kidney toxicity model DSS-induced colitis model LPS-induced endotoxemia model Experimental autoimmune encephalomyelitis (EAE) Tail-suspended rat model STZ-induced diabetic mice model ACLT-induced osteoarthritis model IMQ-induced psoriasis model Chronic-binge ethanol feeding ALD mouse model	Administration	Dosage	Frequency	Description	References
C57BL/6 mice	Cisplatin-induced small intestine and kidney toxicity model	Oral gavage	20% (w/v), 500 μL/day	Once daily for 5 days	To investigate the protective effect of D-Mannose on cisplatin-induced small intestine and kidney toxicity. Results showed that D-Mannose effectively protected the small intestine and kidney from cisplatin-induced damage by activating AMPK and suppressing GSDME cleavage.	Cell Res. 2023 Dec;33(12):904-922.
Mice	DSS-induced colitis model	Oral	15% , dissolved in drinking water	Continuous administration for 8 days	To evaluate the effect of mannose on colitis development. Results showed that mannose significantly ameliorated DSS-induced colitis symptoms, including body weight loss, colon shortening, and histological damage.	Cell Mol Immunol. 2023 Feb;20(2):119-130.
Mice (Balb/c)	LPS-induced endotoxemia model	Intraperitoneal injection	2 g/kg	Hourly, up to six times	Reduced serum IL-1β levels and improved survival rate	Nat Commun. 2020 Dec 11;11(1):6343.
Mice	Experimental autoimmune encephalomyelitis (EAE)	Intraperitoneal injection	450 mg/kg	Once daily from the day of induction until day 19	To evaluate the effect of D-mannose on EAE symptoms. D-mannose treatment improved EAE symptoms, reduced MPO-mediated oxidative stress, and partially blocked macrophage/microglia phagocytosis.	Proc Natl Acad Sci U S A. 2021 Nov 2;118(44):e2107663118.
Rats	Tail-suspended rat model	Intragastric administration	1.1 M	Once daily for 28 days	Prevented bone loss and urinary tract infections under weightlessness	J Transl Med. 2023 Jan 9;21(1):8.
Balb/c mice	STZ-induced diabetic mice model	Topical application on skin	3% (w/v)	Once daily for 13 days	D-Mannose significantly improved skin wound healing in diabetic mice, inhibited AGEs generation, and activated the AMPK/Nrf2/HO-1 signaling pathway.	Mol Med. 2025 Jan 18;31(1):15.
C57BL/6J mice	ACLT-induced osteoarthritis model	Oral drinking water	20%, in drinking water	Administration started two weeks before surgery and continued until 4 and 8 weeks post-surgery	To evaluate the effect of D-mannose on ACLT-induced osteoarthritis progression. Results showed that D-mannose significantly alleviated cartilage degeneration, reduced OARSI scores, and inhibited HIF-2α-mediated chondrocyte ferroptosis.	Cell Prolif. 2021 Nov;54(11):e13134.
C57BL/6 mice	IMQ-induced psoriasis model	Oral	20% (w/v), 200mL	Twice daily for one week	To evaluate the impact of D-mannose on IMQ-induced psoriasis, results showed that D-mannose treatment significantly alleviated skin inflammation.	Front Immunol. 2022 Feb 28;13:840755.
C57BL/6 mice	Chronic-binge ethanol feeding ALD mouse model	Drinking-water supplementation	1%, 2%, 3% (w/v)	11 days	To evaluate the effect of D-mannose on hepatic steatosis in ALD mice. Results showed that D-mannose significantly alleviated ethanol-induced hepatic steatosis, reduced serum ALT and AST levels, decreased hepatic TG and TC contents, and confirmed reduced hepatic lipid deposition via H&E and Oil Red O staining.	Front Immunol. 2022 Apr 7;13:877650.

Species

C57BL/6 mice Mice Mice (Balb/c) Mice Rats Balb/c mice C57BL/6J mice C57BL/6 mice C57BL/6 mice

Animal Model

Cisplatin-induced small intestine and kidney toxicity model DSS-induced colitis model LPS-induced endotoxemia model Experimental autoimmune encephalomyelitis (EAE) Tail-suspended rat model STZ-induced diabetic mice model ACLT-induced osteoarthritis model IMQ-induced psoriasis model Chronic-binge ethanol feeding ALD mouse model

Administration

Dosage

Frequency

Description

References

C57BL/6 mice

Cisplatin-induced small intestine and kidney toxicity model

Oral gavage

20% (w/v), 500 μL/day

Once daily for 5 days

To investigate the protective effect of D-Mannose on cisplatin-induced small intestine and kidney toxicity. Results showed that D-Mannose effectively protected the small intestine and kidney from cisplatin-induced damage by activating AMPK and suppressing GSDME cleavage.

Cell Res. 2023 Dec;33(12):904-922.

Mice

DSS-induced colitis model

Oral

15% , dissolved in drinking water

Continuous administration for 8 days

To evaluate the effect of mannose on colitis development. Results showed that mannose significantly ameliorated DSS-induced colitis symptoms, including body weight loss, colon shortening, and histological damage.

Cell Mol Immunol. 2023 Feb;20(2):119-130.

Mice (Balb/c)

LPS-induced endotoxemia model

Intraperitoneal injection

2 g/kg

Hourly, up to six times

Reduced serum IL-1β levels and improved survival rate

Nat Commun. 2020 Dec 11;11(1):6343.

Mice

Experimental autoimmune encephalomyelitis (EAE)

Intraperitoneal injection

450 mg/kg

Once daily from the day of induction until day 19

To evaluate the effect of D-mannose on EAE symptoms. D-mannose treatment improved EAE symptoms, reduced MPO-mediated oxidative stress, and partially blocked macrophage/microglia phagocytosis.

Proc Natl Acad Sci U S A. 2021 Nov 2;118(44):e2107663118.

Rats

Tail-suspended rat model

Intragastric administration

1.1 M

Once daily for 28 days

Prevented bone loss and urinary tract infections under weightlessness

J Transl Med. 2023 Jan 9;21(1):8.

Balb/c mice

STZ-induced diabetic mice model

Topical application on skin

3% (w/v)

Once daily for 13 days

D-Mannose significantly improved skin wound healing in diabetic mice, inhibited AGEs generation, and activated the AMPK/Nrf2/HO-1 signaling pathway.

Mol Med. 2025 Jan 18;31(1):15.

C57BL/6J mice

ACLT-induced osteoarthritis model

Oral drinking water

20%, in drinking water

Administration started two weeks before surgery and continued until 4 and 8 weeks post-surgery

To evaluate the effect of D-mannose on ACLT-induced osteoarthritis progression. Results showed that D-mannose significantly alleviated cartilage degeneration, reduced OARSI scores, and inhibited HIF-2α-mediated chondrocyte ferroptosis.

Cell Prolif. 2021 Nov;54(11):e13134.

C57BL/6 mice

IMQ-induced psoriasis model

Oral

20% (w/v), 200mL

Twice daily for one week

To evaluate the impact of D-mannose on IMQ-induced psoriasis, results showed that D-mannose treatment significantly alleviated skin inflammation.

Front Immunol. 2022 Feb 28;13:840755.

C57BL/6 mice

Chronic-binge ethanol feeding ALD mouse model

Drinking-water supplementation

1%, 2%, 3% (w/v)

11 days

To evaluate the effect of D-mannose on hepatic steatosis in ALD mice. Results showed that D-mannose significantly alleviated ethanol-induced hepatic steatosis, reduced serum ALT and AST levels, decreased hepatic TG and TC contents, and confirmed reduced hepatic lipid deposition via H&E and Oil Red O staining.

Front Immunol. 2022 Apr 7;13:877650.

D-Mannose/D-甘露糖临床研究

NCT号

适应症或疾病

临床期

招募状态

预计完成时间

地点

NCT02180906

Completed

Denmark ... 展开 >> Copenhagen University Hospital, Rigshospitalet Copenhagen, Denmark, 2100 收起 <<

NCT03267407

Active, not recruiting

March 31, 2018

Vietnam ... 展开 >> National Hospital for Tropical Diseases Hanoi, Vietnam, 100000 收起 <<

NCT00717730

Diarrhea Pneu... 展开 >>monia 收起 <<

Phase 2

Completed

India ... 展开 >> Society for Essential Health Action and Training New Delhi, Delhi, India 收起 <<

D-Mannose/D-甘露糖实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

5.55mL

1.11mL

0.56mL

27.75mL

5.55mL

2.78mL

55.51mL

11.10mL

5.55mL

D-Mannose/D-甘露糖技术信息

CAS号	3458-28-4
分子式	C₆H₁₂O₆
分子量	180.16
SMILES Code	O=C[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O
MDL No.	MFCD00799233

别名	D-(+)-甘露糖 ;Carubinose; NSC 26247; (+)-Mannose
运输	蓝冰

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Inert atmosphere,2-8°C

溶解方案

细胞实验：

DMSO: 50 mg/mL(277.54 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H₂O: 50 mg/mL(277.54 mM)

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

配制的工作液建议现用现配，短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02180906	-		Completed	-	Denmark ... 展开 >> Copenhagen University Hospital, Rigshospitalet Copenhagen, Denmark, 2100 收起 <<
NCT03267407	-		Active, not recruiting	March 31, 2018	Vietnam ... 展开 >> National Hospital for Tropical Diseases Hanoi, Vietnam, 100000 收起 <<
NCT00717730	Diarrhea Pneu... 展开 >>monia 收起 <<	Phase 2	Completed	-	India ... 展开 >> Society for Essential Health Action and Training New Delhi, Delhi, India 收起 <<
NCT01833312	Acute Ischemic Stroke	Phase 3	Recruiting	December 2020	Germany ... 展开 >> Department of Neurology, University Hospital Erlangen Recruiting Erlangen, Germany, 91054 Contact: Dimitre Staykov, PD Dr. +4991318533001 dimitre.staykov@uk-erlangen.de 收起 <<
NCT02998879	Alpha-Mannosidosis	Phase 2	Recruiting	February 2020	Austria ... 展开 >> Recruiting Wien, Austria Denmark Recruiting Copenhagen, Denmark France Recruiting Lyon, France Germany Not yet recruiting Hamburg, Germany Recruiting Mainz, Germany Italy Not yet recruiting Trieste, Italy 收起 <<
NCT02865434	Arthritis, Rheumatoid	Phase 1 Phase 2	Active, not recruiting	December 2018	United States, Ohio ... 展开 >> Kettering Medical Center Kettering, Ohio, United States, 45429 收起 <<
NCT02997462	-		Active, not recruiting	December 2019	United States, Michigan ... 展开 >> University of Michigan Health System Ann Arbor, Michigan, United States, 48109 收起 <<
NCT03236272	-		Recruiting	December 31, 2020	China ... 展开 >> Emergency Department, Xinqiao Hospital, Third Military Medical University Recruiting Chongqing, China Contact: HU MINGDONG, MD 收起 <<
NCT02478840	Alpha-Mannosidosis	Phase 3	Completed	-	Denmark ... 展开 >> Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9 Copenhagen, Denmark, DK-2100 收起 <<
NCT00674271	-		Unknown	May 2018	Denmark ... 展开 >> Medical Department M, Aarhus University Hospital Aarhus C, Denmark, 8000 收起 <<
NCT03436134	Kidney Transplantation ... 展开 >> Antibody Mediated Rejection 收起 <<	Not Applicable	Not yet recruiting	March 1, 2021	France ... 展开 >> Grenoble Alpes University Hospital Not yet recruiting La Tronche, France, 38700 Contact: Lionel Rosating, PHD 0476767022 ext 0033 lrostaing@chu-grenoble.fr Contact: Paolo Malvezzi, MD 0476767022 ext 0033 Pmalvezzi@chu-grenoble.fr Principal Investigator: lionel Rostaing, PHD Sub-Investigator: Paolo Malvezzi, MD 收起 <<
NCT02332616	Osteoarthrosis	Phase 3	Completed	-	Denmark ... 展开 >> Bispebjerg Hospital Copenhagen NV, Denmark, 2400 收起 <<
NCT01349738	-		Unknown	May 2013	United States, California ... 展开 >> Scripps Green Hospital La Jolla, California, United States, 92037 收起 <<
NCT02402803	-		Recruiting	October 2019	United States, California ... 展开 >> Cedars Sinai Medical Center Recruiting Los Angeles, California, United States, 90048 Contact: Ying Mou, PhD 310-248-7669 ying.mou@cshs.org Contact: Sophie Yoo, MS 424-315-4306 Jihye.Yoo@cshs.org Principal Investigator: C. Noel Bairey Merz, MD 收起 <<
NCT00984516	Cicatrix Woun... 展开 >>d-healing 收起 <<	Phase 2	Completed	-	United Kingdom ... 展开 >> Renovo Manchester, United Kingdom, M13 9XX 收起 <<
NCT03332940	Nonalcoholic Steatohepatitis ... 展开 >> NASH - Nonalcoholic Steatohepatitis 收起 <<	Phase 1	Active, not recruiting	December 2018	United States, Ohio ... 展开 >> Kettering Medical Center Kettering, Ohio, United States, 45429 收起 <<
NCT01906229	-		Terminated(Slow enrollment and... 展开 >> therefore not possible to reach the estimated enrollment) 收起 <<	-	Denmark ... 展开 >> Intensive Care Unit, 4131, Rigshospitalet Copenhagen Ø, Denmark, 2100 收起 <<
NCT00688389	-		Recruiting	December 31, 2020	Taiwan ... 展开 >> Kaoshing Medical University Chung-Ho Memorial Hospital Recruiting Kaohsiung, Taiwan Contact: Jih-Jin Tsai, MD 886-7-312-1101 ext 5677 jijits@cc.kmu.edu.tw 收起 <<
NCT00957736	-		Terminated(study closed premat... 展开 >>urely upon PI's departure from VICC) 收起 <<	-	United States, Tennessee ... 展开 >> Vanderbilt-Ingram Cancer Center - Cool Springs Nashville, Tennessee, United States, 37064 Vanderbilt-Ingram Cancer Center at Franklin Nashville, Tennessee, United States, 37064 Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232-6838 收起 <<
NCT03157167	Kaposi Sarcoma ... 展开 >> HIV Infections 收起 <<	Phase 1	Recruiting	March 2019	United States, California ... 展开 >> Zuckerberg San Francisco General Hospital Recruiting San Francisco, California, United States, 94143 Contact: Toby A Maurer, MD maurert@derm.ucsf.edu Principal Investigator: Toby A Maurer, MD 收起 <<
NCT00006134	-		Completed	-	United States, Alabama ... 展开 >> University of Alabama Comprehensive Cancer Center Birmingham, Alabama, United States, 35294 United States, Texas University of Texas Medical Branch Galveston, Texas, United States, 77555-0209 University of Texas Health Science Center - Houston Houston, Texas, United States, 77225 收起 <<
NCT00001702	-		Completed	-	United States, Alabama ... 展开 >> University of Alabama Birmingham, Alabama, United States United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01359384	-		Unknown	May 2012	Germany ... 展开 >> Children's Hospital, Goethe-University Not yet recruiting Frankfurt a. Main, Hessen, Germany, 60590 Contact: Martin Rosewich, MD Martin.Rosewich@kgu.de 收起 <<
NCT00001701	-		Completed	-	United States, Alabama ... 展开 >> University of Alabama Birmingham, Alabama, United States 收起 <<
NCT03597152	Recurrent Urinary Tract Infect... 展开 >>ion 收起 <<	Not Applicable	Not yet recruiting	December 31, 2020	-
NCT01889693	-		Completed	-	Korea, Republic of ... 展开 >> Korea University Guro Hospital Seoul, Korea, Republic of, 152-703 收起 <<
NCT01275066	-		Completed	-	-
NCT01680575	-		Recruiting	May 2018	Korea, Republic of ... 展开 >> Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center Recruiting Seoul, Korea, Republic of, 138-736 Contact: Jeong-Yeol Park, M.D., Ph.D. 收起 <<
NCT01275066	MPS IV A	Phase 3	Completed	-	-
NCT00197847	-		Unknown	-	Denmark ... 展开 >> Department of Intensive Care Copenhagen, Copenhagen Couty, Denmark, DK-2730 收起 <<
NCT01893489	Atherosclerosis ... 展开 >> Carotid Atherosclerosis Noninvasive Imaging of Atherosclerosis 收起 <<	Phase 1	Completed	-	Korea, Republic of ... 展开 >> Department of Nuclear Medicine, Institute of Radiation Medicine, Seoul, Korea, Republic of, 110-744 Korea University Guro Hospital Seoul, Korea, Republic of, 152-703 收起 <<
NCT02894931	Dietary Habits ... 展开 >> Serum; Disease Macrophage Atherogenicity Atherosclerosis 收起 <<	Not Applicable	Unknown	August 2018	Israel ... 展开 >> Rambam Health care center Recruiting Haifa, Israel, 320000 Contact: Niroz Abu-Saleh, PhD 972504278858 asniroz@gmail.com 收起 <<
NCT03641690	-		Completed	-	-
NCT02931513	-		Recruiting	June 2021	Denmark ... 展开 >> Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark Recruiting Aarhus C, Region Midtjylland, Denmark, 8000 Contact: Lars Bossen, PhD-student +45 2280 0676 larsbossen@clin.au.dk 收起 <<
NCT02924701	-		Recruiting	June 2021	Denmark ... 展开 >> Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark Recruiting Aarhus C, Region Midtjylland, Denmark, 8000 Contact: Lars Bossen, PhD-student +45 2280 0676 larsbossen@clin.au.dk 收起 <<
NCT02635321	-		Completed	-	Denmark ... 展开 >> Copenhagen Neuromuscular Center Copenhagen, Denmark, 2100 收起 <<
NCT03077711	Urinary Tract Infections, Recu... 展开 >>rrent 收起 <<	Phase 4	Active, not recruiting	June 2019	United States, Illinois ... 展开 >> NorthShore Univeristy HealthSystem Skokie, Illinois, United States, 60076 收起 <<
NCT00001648	-		Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01919931	-		Completed	-	Belgium ... 展开 >> Universitair Ziekenhuis Leuven Leuven, Flemish Brabant, Belgium, 3000 收起 <<
NCT00648102	Breast Cancer ... 展开 >> Colorectal Cancer Pancreatic Cancer Bladder Cancer Ovarian Cancer 收起 <<	Phase 1	Completed	-	United States, Michigan ... 展开 >> Henry Ford Health System Detroit, Michigan, United States, 48202 United States, North Carolina Duke University Durham, North Carolina, United States, 27710 Carolina BioOncology Institute Huntersville, North Carolina, United States, 28078 收起 <<
NCT00388999	Multiple Myeloma	Phase 1	Completed	-	United States, Arkansas ... 展开 >> University of Arkansas for Medical Sciences Little Rock, Arkansas, United States, 72205 收起 <<
NCT00709462	Breast Cancer ... 展开 >> Colorectal Cancer Pancreatic Cancer Bladder Cancer Ovarian Cancer 收起 <<	Phase 1	Completed	-	United States, Michigan ... 展开 >> Henry Ford Health System Detroit, Michigan, United States, 48202 United States, North Carolina Duke University Durham, North Carolina, United States, 27710 Carolina BioOncology Institute Cancer Huntersville, North Carolina, United States, 28078 收起 <<
NCT02702765	Wilsons Disease	Not Applicable	Recruiting	February 2020	Denmark ... 展开 >> Department of Hepatology and Gastroenterology, Aarhus University Hospital Recruiting Aarhus, Denmark, 8000 Contact: Jessica Björklund, Research-year student 004560748993 jebjoe@rm.dk 收起 <<
NCT00415311	Liver Transplantation	Phase 1	Terminated(Sponsor decision to... 展开 >> terminate the study) 收起 <<	-	United States, California ... 展开 >> University of California San Francisco San Francisco, California, United States, 94143 United States, Nebraska Nebraska Medical Center Omaha, Nebraska, United States, 68198-7400 United States, New York Mount Sinai School of Medicine New York, New York, United States, 10029 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 372321 收起 <<
NCT00520325	Cancer Hemato... 展开 >>logic Diseases Fever Neutropenia 收起 <<	Phase 1	Withdrawn(Sponsor decision to ... 展开 >>terminate the study) 收起 <<	-	-
NCT00664352	Wound	Phase 1 Phase 2	Completed	-	United Kingdom ... 展开 >> 09Clinical Trials Unit, Renovo Limited Manchester, United Kingdom, M13 9XX 收起 <<
NCT03457038	Septic Shock	Not Applicable	Recruiting	January 2019	France ... 展开 >> University Hospital Toulouse Recruiting Toulouse, France, 31059 Contact: Eric Oswald, MD 5 67 69 04 17 ext 33 oswald.e@chu-toulouse.fr Contact: Isabelle Olivier, PhD 5 61 77 70 51 ext 33 olivier.i@chu-toulouse.fr 收起 <<
NCT00000886	HIV Infections	Phase 1	Completed	-	United States, New York ... 展开 >> Univ. of Rochester AVEG Rochester, New York, United States United States, Tennessee Vanderbilt Univ. Hosp. AVEG Nashville, Tennessee, United States, 37232 United States, Washington UW - Seattle AVEG Seattle, Washington, United States, 98144 收起 <<
NCT00984854	Cicatrix Re-e... 展开 >>pithelialisation 收起 <<	Phase 1	Completed	-	United Kingdom ... 展开 >> Renovo Manchester, United Kingdom, M13 9XX 收起 <<
NCT00854412	Obesity Weigh... 展开 >>t Loss 收起 <<	Not Applicable	Completed	-	-
NCT00678028	-		Completed	-	Israel ... 展开 >> Ha'Emek Medical Center Afula, Israel, 18101 收起 <<
NCT00886496	Fever, Sweats, and Hot Flashes... 展开 >> Infection Leukemia Lymphoma Myelodysplastic Syndromes Neutropenia Unspecified Childhood Solid Tumor, Protocol Specific 收起 <<	Phase 1	Withdrawn(No participants enro... 展开 >>lled. IND withdrawn.) 收起 <<	-	United States, California ... 展开 >> Children's Hospital of Orange County Orange, California, United States, 92868 United States, District of Columbia Children's National Medical Center Washington, District of Columbia, United States, 20010-2970 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT03753451	Periodontal Diseases	Not Applicable	Completed	-	Brazil ... 展开 >> INCOR- Heart Institute Sao Paulo, São Paulo, Brazil, 05403900 INCOR - Heart Institute São Paulo, Brazil, 05403-900 收起 <<
NCT03395288	Urinary Tract Infections	Phase 2 Phase 3	Recruiting	December 2019	United States, Missouri ... 展开 >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: administrative assistant 314-747-1402 收起 <<
NCT01014494	Tendon Injuries	Not Applicable	Unknown	December 2011	United Kingdom ... 展开 >> Mr P Gillespie Recruiting Addenbrooke's Hospital, Cambridge, Cambridge, United Kingdom, CB2 0QQ Contact: Patrick Gillespie 01223 274632 Patrick.gillespie@addenbrookes.nhs.uk University Hospital of South Manchester NHS Foundation Trust Recruiting Manchester, Greater Manchester, United Kingdom, M23 9LT Contact: Miss V C Lees +44 (0) 161 291 6648 Principal Investigator: Vivien C Lees Mr F Schreuder Recruiting The Lister Hospital, Stevenage, Hertfordshire, United Kingdom Contact: Mr Schreuder 01438 781162 Fred.schreuder@nhs.net Mr R Dunn Recruiting Salisbury District Hospital, Salisbury, United Kingdom, SP2 8BJ Contact: Roderick Dunn 01722 336262 ext 3555 sue.dubber@salisbury.nhs.uk Mr D Warwick Recruiting Southampton General Hospital, Southampton, United Kingdom, SO16 6YD Contact: David Warwick 023 8079 5212 davidjwarwick@btinternet.com Contact: Elaine Hayward 02380 794 989 elaine.hayward@suht.swest.nhs.uk Royal London Hospital, Barts and The London Hospital Recruiting London, United Kingdom, E1 1BB Contact: Kamal El-Ali 07986 693062 Kamal.El-Ali@bartsandthelondon.nhs.uk Principal Investigator: Raj Ragoowansi Sub-Investigator: Kamal El Ali Royal Free Hospital Recruiting London, United Kingdom, NW3 2QG Contact: Donald Dewar 020 7794 0500 ext 31302 Principal Investigator: Donald Dewar Chelsea & Westminster Hospital Recruiting London, United Kingdom, SW10 9NH Contact: Mr Chakrabarty 020 8237 2777 ext 55490 khchakrabarty@yahoo.com Contact: Beryl De Souza bds@dr.com Principal Investigator: Kaushik Chakrabarty Sub-Investigator: Beryl De Souza Abertawe Bro Morgannwg University Nhs Trust Recruiting Swansea, United Kingdom, SA12 7BR Contact: Mr D Boyce +44 (0) 1792 703722 Principal Investigator: Mr D Boyce 收起 <<
NCT01808755	-		Completed	-	-
NCT02823132	-		Completed	-	France ... 展开 >> Centre Hospitalier Universitaire Dijon, France, 21079 收起 <<
NCT03497598	Urinary Tract Infections	Phase 4	Recruiting	June 2021	Switzerland ... 展开 >> Kantonsspital Aarau Recruiting Aarau, Switzerland, 5001 Contact: Gloria Ryu, Dr. med 收起 <<
NCT01808755	Recurrent Urinary Tract Infect... 展开 >>ion 收起 <<	Phase 3	Completed	-	Italy ... 展开 >> Urology Department Fondazione IRCCS Policlinico San Matteo Pavia, Italy, 27100 收起 <<
NCT02397291	IUGR Pregnanc... 展开 >>y 收起 <<	Not Applicable	Suspended	June 2020	United States, Colorado ... 展开 >> University of Colorado Denver Anschutz Medical Campus Aurora, Colorado, United States, 80045 收起 <<
NCT02490046	Multiple Sclerosis ... 展开 >> Recurrent Urinary Tract Infections 收起 <<	Phase 1	Unknown	November 2015	United Kingdom ... 展开 >> The National Hospital for Neurology and Neurosurgery Recruiting London, United Kingdom, WC1N 3BG Contact: Jalesh Panicker, MD, FRCP 020 344 84713 j.panicker@ucl.ac.uk Contact: Véronique Phé, MD 020 344 84713 Veronique.Phe@uclh.nhs.uk Sub-Investigator: Mahreen Pakzad, FRCS Principal Investigator: Jalesh Panicker, MD, FRCP Sub-Investigator: Véronique Phé, MD 收起 <<

D-Mannose/D-甘露糖 {[allProObj[0].p_purity_real_show]}

D-Mannose/D-甘露糖纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

D-Mannose/D-甘露糖质控信息

D-Mannose/D-甘露糖细胞实验

D-Mannose/D-甘露糖动物实验

D-Mannose/D-甘露糖临床研究

D-Mannose/D-甘露糖实验方案

D-Mannose/D-甘露糖技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

D-Mannose/D-甘露糖 {[allProObj[0].p_purity_real_show]}

D-Mannose/D-甘露糖 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

D-Mannose/D-甘露糖 质控信息

D-Mannose/D-甘露糖 细胞实验

D-Mannose/D-甘露糖 动物实验

D-Mannose/D-甘露糖 临床研究

D-Mannose/D-甘露糖 实验方案

D-Mannose/D-甘露糖 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

D-Mannose/D-甘露糖纯度/质量文件产品仅供科研

D-Mannose/D-甘露糖质控信息

D-Mannose/D-甘露糖细胞实验

D-Mannose/D-甘露糖动物实验

D-Mannose/D-甘露糖临床研究

D-Mannose/D-甘露糖实验方案

D-Mannose/D-甘露糖技术信息